Anticoagulant evaluation of 1,3,4-oxadiazole derivatives derived from benzimidazole

Abstract

In the present study, a series of 1,3,4-oxadiazole derivatives (4a-4k) derived from benzimidazole were evaluated for ex vivo anticoagulant activity. The anticoagulant study was performed for increase in prothrombin time (PT) and activated partial thromboplastin time (aPTT) at a test dose of 25 mg kg^-1. The results of ex vivo anticoagulant evaluation revealed that the tested compounds 4a-4k exhibited moderate increase in PT with respect to acenocoumarol (1 mg kg^-1) employed as reference drug for increase in PT. While the compounds 4a-4k exhibited minimal increase in aPTT in comparison to unfractionated heparin (500 IU kg^-1) employed as reference drug for increase in aPTT. Compounds, 4c, 4b and 4k exhibited substantial anticoagulant activity with increase in PT 32 ± 0.7, 36 ± 0.5 and 41 ± 0.4 s, respectively to that of the reference drug acenocoumarol (48 ± 0.5 s).